Drug Type Small molecule drug |
Synonyms AZD 4831, AZD4831 |
Target |
Mechanism MPO inhibitors(Myeloperoxidase inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
Regulation- |
Molecular FormulaC15H15ClN4OS |
InChIKeyBHKKSKOHRFHHIN-MRVPVSSYSA-N |
CAS Registry1933460-19-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Heart failure with normal ejection fraction | Phase 3 | US | 30 Jun 2021 | |
Heart failure with normal ejection fraction | Phase 3 | JP | 30 Jun 2021 | |
Heart failure with normal ejection fraction | Phase 3 | AU | 30 Jun 2021 | |
Heart failure with normal ejection fraction | Phase 3 | BE | 30 Jun 2021 | |
Heart failure with normal ejection fraction | Phase 3 | BR | 30 Jun 2021 | |
Heart failure with normal ejection fraction | Phase 3 | BG | 30 Jun 2021 | |
Heart failure with normal ejection fraction | Phase 3 | CA | 30 Jun 2021 | |
Heart failure with normal ejection fraction | Phase 3 | CZ | 30 Jun 2021 | |
Heart failure with normal ejection fraction | Phase 3 | DK | 30 Jun 2021 | |
Heart failure with normal ejection fraction | Phase 3 | FR | 30 Jun 2021 |
Phase 2 | 41 | (AZD4831) | wyuimcpwfe(bwxkwxdala) = yusricmkwe ytrkdwhtyv (arjecfoboo, xfcrfckpys - emxlbevcen) View more | - | 19 Jul 2021 | ||
Placebo (Placebo) | wyuimcpwfe(bwxkwxdala) = uvxwvqcqnq ytrkdwhtyv (arjecfoboo, luomhucmdy - hnrusnfhmm) View more |